Showing posts with label #drug. Show all posts
Showing posts with label #drug. Show all posts

Monday, October 20, 2025

More Magic Mushrooms?

 




More Magic Mushrooms?

Kylee French
BIOL-2110-001 - GENETICS Professor Guy F. Barbato October 20, 2025

    Psilocybin is a psychedelic drug that is produced in mushrooms, and there is no real need for mushrooms to produce this compound. Or is there? This trait was apparently so beneficial for mushrooms that it evolved in two distantly related types of mushrooms. One part that shows these mushrooms are distantly related is their different lifestyles. Psilocybe mushrooms thrive on decaying material such as decomposing organic matter or cow dung. Inocybe mushrooms are symbiotic organisms that form intimate, mutually beneficial relationships with trees. The article "How Psychedelic Mushrooms Evolved Their Magic", explains how these two separate groups of mushrooms independently evolved the ability to produce psilocybin, a powerful psychedelic compound. Surprisingly, they use completely different genetic and biochemical pathways to create the same molecule, demonstrating nature’s multiple solutions to the same problem. The article quotes the process by stating, "Psilocybe and Inocybe both use the same amino acid starting point to produce psilocybin. But from there, the mushrooms follow separate road maps of genes and enzymes. Midway through, they meet at an intermediate molecular point before parting ways once again — only to converge on a shared end product" (Nuwer, 2025). This study not only provides insight into fungal evolution but also opens new possibilities for synthesizing psilocybin for research and therapeutic purposes.

    In addition, I find this article revolutionary because it shifts our perspective on psilocybin. While we often think of it simply as a psychedelic drug, the research shows it can now be studied through genetics for its potential benefits. Interestingly, in 1958, Albert Hofmann, the Swiss chemist who discovered LSD, became the first researcher to isolate psilocybin from Psilocybe mushrooms, even though at the time it was primarily used as a drug rather than for scientific study. Now that we know the compound is produced independently by two separate mushroom species, it suggests that psilocybin serves an important biological function. This discovery also points to possible new methods for synthesizing psilocybin, which could greatly expand our knowledge of its effects on the brain, its potential therapeutic uses, and how genetic pathways create bioactive compounds.

References

Nuwer, R. (2025, October 18). How Psychedelic Mushrooms Evolved Their Magic. New York Times. Retrieved October 20, 2025, from https://www.nytimes.com/2025/10/18/science/how-psychedelic-mushrooms-evolved-their-magic.html

Thursday, November 28, 2019

A precision drug for prostate cancer may slow the disease’s spread


 

Links:
Article: https://www.sciencenews.org/article/prostate-cancer-drug-olaparib-slow-spread
Related Article: https://www.google.com/amp/s/www.bbc.com/news/amp/health-49877843


Recently, researchers have discovered that a drug used to treat breast and ovarian cancers is also tied to certain genetic mutations that may help combat some of the most severe cases of prostate cancer.
Researchers tested the drug, called olaparib, in a randomized clinical trial of nearly 400 men with advanced prostate cancer and a mutation in one of several genes involved in repairing damaged DNA, such as BRCA1 and BRCA2
Overall in men given olaparib, the disease progressed more slowly compared with those on standard treatment drugs that deprive cancer cells of the male hormone testosterone. After a year, about 22 percent of men taking olaparib had no signs that their cancer was progressing, compared with 13.5 percent of men on the standard treatments, the researchers reported September 30 in Barcelona at the European Society of Medical Oncology meeting.

This was a very interesting article to read. Although it is too early to say how the drug will impact overall survival , this new treatment looks promising so far, potentially buying some patients a few more months